Baojin Zhu

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Clinical comparability of schizophrenia patients at two public mental health systems
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Adm Policy Ment Health 30:231-45. 2003
  2. ncbi Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
  3. ncbi Costs of treating patients with schizophrenia who have illness-related crisis events
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, USA
    BMC Psychiatry 8:72. 2008
  4. ncbi Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder
    Baojin Zhu
    Eli Lilly and Company Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 23:2805-14. 2007
  5. ncbi Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Curr Med Res Opin 27:633-41. 2011
  6. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
  7. ncbi Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 6:8. 2006
  8. ncbi Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 67:453-60. 2006
  9. ncbi Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 5:26. 2005
  10. ncbi Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus
    Zhenxiang Zhao
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Med Econ 13:748-59. 2010

Detail Information

Publications23

  1. ncbi Clinical comparability of schizophrenia patients at two public mental health systems
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Adm Policy Ment Health 30:231-45. 2003
    ....
  2. ncbi Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
    ..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
  3. ncbi Costs of treating patients with schizophrenia who have illness-related crisis events
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, USA
    BMC Psychiatry 8:72. 2008
    ..This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia...
  4. ncbi Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder
    Baojin Zhu
    Eli Lilly and Company Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 23:2805-14. 2007
    ..Atypical antipsychotics are playing an increasing role in the treatment of bipolar disorder. The objective of this study was to assess the medication treatment patterns and costs associated with different atypical antipsychotics...
  5. ncbi Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Curr Med Res Opin 27:633-41. 2011
    ..This study evaluated factors associated with clopidogrel use and adherence in ACS patients following PCI...
  6. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
    ..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...
  7. ncbi Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 6:8. 2006
    ..This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia...
  8. ncbi Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 67:453-60. 2006
    ....
  9. ncbi Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 5:26. 2005
    ..This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications...
  10. ncbi Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus
    Zhenxiang Zhao
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Med Econ 13:748-59. 2010
    ..This study compared differences in healthcare costs and resource utilization for acute coronary syndrome (ACS) patients with and without diabetes mellitus (DM)...
  11. ncbi A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 67:1114-23. 2006
    ..This study aimed to prospectively identify the best single predictor and the best set of predictors of risk for nonadherence with anti-psychotic medication in the treatment of patients with schizophrenia...
  12. ncbi Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study
    Haya Ascher-Svanum
    U S Outcomes Research, Eli Lilly and Co, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    J Clin Psychiatry 69:1580-8. 2008
    ..The objective of this study was to compare the 3-year course of schizophrenia between persons with tardive dyskinesia (TD) and persons without TD on multiple outcome measures...
  13. ncbi Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
    Psychiatr Serv 59:315-7. 2008
    ..This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia...
  14. ncbi Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial
    Baojin Zhu
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 21:555-64. 2005
    ....
  15. ncbi Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Outcomes Research, Indianapolis, IN, USA
    Patient Prefer Adherence 2:67-77. 2008
    ..To compare adherence and persistence to typical versus atypical antipsychotics and between specific atypical agents in the usual care of schizophrenia and to examine the association between adherence and persistence...
  16. ncbi Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database
    Zhongyun Zhao
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    CNS Drugs 18:157-64. 2004
    ..To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia...
  17. ncbi Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
    ..abstract:..
  18. ncbi The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder
    Baojin Zhu
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Nerv Ment Dis 197:136-9. 2009
    ..001). Comorbid depression and pain had significant impact on costs, especially those with pain or with both depression and pain. This suggests that an optimal strategy for GAD should take into account comorbid pain and depression...
  19. ncbi A Bayesian approach to the statistical analysis of device preference studies
    Haoda Fu
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharm Stat 11:149-56. 2012
    ..In this paper, we propose a Bayesian statistical method to analyze the data from preference trials. We demonstrate that the new Bayesian estimator enjoys some optimal properties versus the frequentist estimator...
  20. ncbi The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data
    Baojin Zhu
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Cardiovasc Pharmacol 57:317-24. 2011
    ..0001), regardless of sex, body weight, or age and as early as 30 minutes in the diabetic subgroup. A prasugrel 60-mg LD produces significantly faster onset and greater IPA compared with a clopidogrel 300-mg LD or 600-mg LD...
  21. ncbi Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin
    Christine Y Yu
    Eli Lilly and Company, Indianapolis, IN, USA
    Curr Med Res Opin 28:187-94. 2012
    ..The aim of this study was to assess the effect of pitavastatin compared with rosuvastatin on steady-state pharmacodynamics (PD) of warfarin by measuring INR in healthy adult subjects...
  22. ncbi Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
    Psychiatr Serv 58:482-8. 2007
    ....
  23. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...